Roman Butler Fullerton & Co. Buys New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS)

Roman Butler Fullerton & Co. purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,867 shares of the company's stock, valued at approximately $654,000.

Other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new position in shares of Krystal Biotech in the fourth quarter worth about $34,391,000. Soleus Capital Management L.P. lifted its position in shares of Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock valued at $56,144,000 after acquiring an additional 141,400 shares in the last quarter. GAMMA Investing LLC boosted its stake in Krystal Biotech by 50,249.4% in the 1st quarter. GAMMA Investing LLC now owns 121,342 shares of the company's stock worth $21,878,000 after purchasing an additional 121,101 shares during the period. Raymond James Financial Inc. purchased a new position in Krystal Biotech during the 4th quarter worth approximately $15,989,000. Finally, Price T Rowe Associates Inc. MD grew its position in Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after purchasing an additional 71,200 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on KRYS. Chardan Capital reaffirmed a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. Citigroup decreased their price objective on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a report on Friday, May 16th. Guggenheim lowered their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, May 6th. Finally, Jefferies Financial Group assumed coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target for the company. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $211.13.

Krystal Biotech Price Performance

KRYS stock opened at $130.02 on Wednesday. The business has a fifty day moving average price of $145.29 and a 200 day moving average price of $160.34. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $219.34. The stock has a market capitalization of $3.76 billion, a price-to-earnings ratio of 31.25 and a beta of 0.65.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The company had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. On average, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.